Treatment of Candida ciferrii Infection in Adults
For invasive Candida ciferrii infection in adults, initiate treatment with an echinocandin (anidulafungin 200 mg loading dose then 100 mg daily, micafungin 100 mg daily, or caspofungin 70 mg loading dose then 50 mg daily) as first-line therapy, given this species' documented fluconazole resistance. 1
Critical Species-Specific Considerations
Candida ciferrii is inherently fluconazole-resistant 2. This fundamentally changes the treatment approach from typical Candida infections. The 2001 case report documenting the first invasive C. ciferrii infection specifically identified fluconazole resistance through in vitro susceptibility testing, emphasizing that this species should be treated as azole-resistant from the outset 2.
First-Line Treatment Regimen
Echinocandin Therapy (Preferred)
- Anidulafungin: 200 mg IV loading dose, then 100 mg IV daily
- Micafungin: 100 mg IV daily
- Caspofungin: 70 mg IV loading dose, then 50 mg IV daily
The IDSA 2016 guidelines provide strong recommendation for echinocandins as initial therapy for invasive candidiasis, particularly when azole resistance is suspected or documented 1. Given C. ciferrii's known fluconazole resistance, echinocandins are the only appropriate first-line option.
Alternative Therapy
Amphotericin B Formulations
If echinocandins cannot be used (due to resistance, toxicity, or unavailability):
Amphotericin B maintains broad activity against most Candida species and should be considered when echinocandin therapy fails or is contraindicated 3.
Essential Adjunctive Measures
Source Control
- Remove central venous catheters if present (strong recommendation) 1, 4
- Drain any abscesses or collections
- Remove or replace urinary catheters if applicable 1
Susceptibility Testing
Mandatory antifungal susceptibility testing should be performed on all C. ciferrii isolates to guide ongoing therapy, particularly testing for echinocandin susceptibility 1. While fluconazole resistance is expected, echinocandin susceptibility patterns must be confirmed.
Duration of Therapy
Continue treatment for at least 2 weeks after documented clearance of Candida from bloodstream and resolution of clinical signs attributable to infection 1. If metastatic complications develop (endophthalmitis, endocarditis, osteomyelitis), extend therapy for several weeks to months depending on the site 1.
Common Pitfalls to Avoid
- Never use fluconazole for C. ciferrii, even as step-down therapy—this species is inherently resistant 2
- Do not delay susceptibility testing—assume azole resistance but confirm echinocandin susceptibility 1
- Do not overlook catheter removal—failure to remove infected catheters significantly increases mortality 1, 4
- Avoid premature discontinuation—ensure documented clearance before stopping therapy 1
Special Populations
Elderly Patients
Echinocandins are particularly appropriate for elderly patients due to minimal drug-drug interactions and favorable safety profile compared to azoles or amphotericin B 5, 6. Dose adjustments are generally not required for age alone.
Critically Ill/ICU Patients
Echinocandins remain first-line even in severe sepsis or septic shock 1, 7. The 2016 IDSA guidelines specifically recommend echinocandins for critically ill patients with invasive candidiasis 1.
Monitoring Requirements
- Repeat blood cultures every 24-48 hours until clearance documented
- Ophthalmologic examination to rule out endophthalmitis
- Imaging of liver, spleen, and other potential metastatic sites if candidemia persists
- Renal and hepatic function monitoring during therapy
The emergence of C. ciferrii as a fluconazole-resistant pathogen underscores the importance of species identification and susceptibility testing in all invasive Candida infections 2, 8.